Street Calls of the Week
IRVINE, Calif. - Biomerica Inc. (NASDAQ:BMRA) announced Wednesday the appointment of Gary Huff to its Board of Directors as an independent member. Huff previously served as Chief Executive Officer of LabCorp Diagnostics, one of the world’s largest clinical laboratories. The appointment comes at a crucial time for the company, which according to InvestingPro data, maintains a healthy balance sheet with more cash than debt and a current ratio of 2.8x, though it faces profitability challenges with negative earnings in the last twelve months.
Huff brings decades of leadership experience in the diagnostics and healthcare services industry. Throughout his career, he has managed commercial laboratories of various sizes across both public and private equity sectors.
Currently, Huff operates his own advisory firm and serves on the boards of Lighthouse Labs and Tribal Diagnostics. He has also provided advisory services to health systems and various global consulting and investment firms, including McKinsey & Company and Cerberus Capital Management.
"Gary’s exceptional track record of building successful diagnostics businesses, forging strategic partnerships, and delivering shareholder value will be invaluable as Biomerica continues to advance its innovative diagnostic portfolio," said Zack Irani-Cohen, Chief Executive Officer of Biomerica. The company’s stock has shown resilience with an 18% year-to-date return, though InvestingPro analysis indicates the stock is currently trading below its Fair Value. Investors can access more detailed insights and 6 additional ProTips through InvestingPro’s comprehensive analysis platform.
Huff expressed enthusiasm about joining Biomerica’s board, noting the potential of the company’s inFoods IBS product to "transform how patients and physicians manage the widespread condition of irritable bowel syndrome."
The inFoods IBS test identifies patient-specific food triggers responsible for IBS symptoms through a finger-stick blood sample, allowing physicians to recommend targeted dietary changes. A multicenter clinical trial published in Gastroenterology in June 2025 showed statistically significant outcomes for patients who eliminated identified trigger foods.
Biomerica develops, manufactures, and markets diagnostic and therapeutic products used at point-of-care settings and in clinical laboratories, with a primary focus on gastrointestinal and inflammatory diseases.
This information is based on a company press release statement.
In other recent news, Biomerica Inc. has announced several significant developments. The United Arab Emirates Ministry of Health and Prevention has approved Biomerica’s Fortel Kidney Test for home use, which detects low levels of albumin in urine, an early marker of kidney disease. This test is particularly beneficial for individuals with diabetes and hypertension. Additionally, the UAE has also approved Biomerica’s Fortel Ulcer Test, a 10-minute rapid diagnostic test for Helicobacter pylori, a bacterium linked to peptic ulcers and gastric cancer.
In other advancements, Biomerica has launched the inFoods IBS Trigger Food Navigator, an AI-backed tool designed to help Irritable Bowel Syndrome patients manage their dietary restrictions by identifying specific trigger foods. This tool complements the company’s existing inFoods IBS test, which typically identifies two to four trigger foods per patient. These recent approvals and product launches reflect Biomerica’s ongoing efforts to expand its diagnostic offerings and provide innovative solutions for managing health conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.